Gerson Pharma Solutions

Gerson Pharma Solutions, LLC, was formed in 2010 to assist pharmaceutical and biotech companies in the design and execution of their preclinical drug development programs to support human testing and the successful registration of their drug candidates. Prior to forming Gerson Pharma Solutions Dr. Gerson was Vice President of Preclinical R&D at End... o Pharmaceuticals and later served as Vice President of Scientific In-Licensing at Endo. As Vice President of Preclinical R&D he was responsible for all preclinical disciplines supporting Endo's drug development activities with direct responsibility for Toxicology, Drug Metabolism/ Pharmacokinetics, Pharmacology and Pharmaceutics Development. While at Endo Dr. Gerson lead all preclinical development activities culminating in the US FDA approval of Opana® and Opana ER®. As Vice President of Scientific In-Licensing Dr Gerson evaluated the scientific merit and attractiveness of potential acquisitions and then organized and lead multidisciplinary diligence teams to perform in-depth evaluations of the acquisitions. Prior to his tenure at Endo Pharmaceuticals, Dr Gerson held leadership positions in the Preclinical Toxicology Departments at Merck, Sterling-Winthrop, DuPont-Merck and DuPont Pharmaceuticals. During his 25+ year tenure in the pharmaceutical industry, Dr. Gerson was responsible for the preclinical development of drugs from a broad range of therapeutic classes, medical imaging agents and drug delivery devices. He wrote or directed the preparation of over thirty IND packages and the nonclinical sections of four successful NDA/MAA submissions (Opana®, Zocor®, Definity® and Sustiva®). Dr. Gerson received his B.A. in Chemistry, M.S. in Pharmacology and his Ph.D. in Toxicology, is board certified in General Toxicology by the American Board of Toxicology and is a member of the Roundtable of Toxicology Consultants and the Society of Toxicology.Read More